Phase 2 Parkinson's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of joining the study
• People who are willing and able to follow the study procedures and have given written consent to participate
• People who are either male, or female and fall into one of these categories: have had both ovaries and/or uterus surgically removed, have gone through menopause (no periods for more than one year), are not breastfeeding, or have had a negative pregnancy blood test at screening
• People who have been medically stable for at least 30 days before joining, and remain stable up to the time of the study scan
• For the Lewy body disease group: People who have been diagnosed with Parkinson's disease (PD) or Dementia with Lewy Bodies (DLB) for at least 6 months before joining
• For the non-Lewy body disease group: People who have been diagnosed with a neurological or brain-related condition that a neurologist has determined is unlikely to be Parkinson's disease or Dementia with Lewy Bodies, based on accepted medical and imaging assessments

Who may not be able to join:

• People who have previously been in this study, or who have taken part in another medical research study involving an investigational product or medical device within the last 30 days
• People with a known or suspected history of serious allergic reactions, including severe allergic shock (anaphylaxis), to any part of the imaging agent used in this study (18F-mFBG)
• People with another serious, life-threatening illness where life expectancy is less than one year, or where joining the study could interfere with their medical care
• People with a documented history of ischemic heart disease (such as a prior heart attack or unstable chest pain) or any diagnosis of heart failure
• People with certain serious non-heart-related medical conditions that cause significantly elevated levels of specific hormones in the blood, including a tumour called pheochromocytoma
• People who experience claustrophobia (fear of enclosed spaces) or have a movement condition that would prevent them from lying still on their back for up to 20 minutes
• People with significantly reduced kidney function, as measured by a blood test showing creatinine levels above a certain threshold
• People taking medications known to interfere with how the imaging agent works, if those medications cannot be safely stopped for 24 hours before the study procedures (confirm with trial site)
• People who have taken part in research involving radiation exposure in the past 12 months, where joining this study would bring their total research-related radiation dose above a set safety limit

Important: Always verify eligibility with the trial site directly before applying.